Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relationship Conflict Clear all
Terminated Phase 4 Interventional

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

NCT00312351
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2007 · Synced Jun 10, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

NCT04614246
View directory record Official record
Conditions
Endometriosis
Interventions
BAY1817080, Elagolix, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jun 10, 2026, 10:02 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

NCT04002310
View directory record Official record
Conditions
Macular Degeneration
Interventions
BI 754132
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Beverly Hills, California • Pensacola, Florida • Winter Haven, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Strength At Home: Veterans' Program (PTSD-Focused Therapy for Anger and Relationship Conflict Among OEF/OIF Veterans)

NCT01435512
View directory record Official record
Conditions
Domestic Violence
Interventions
PTSD-Focused CBT for Partner Violence
Behavioral
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Jun 10, 2026, 10:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Drug Abuse Treatment Outcomes

NCT01678833
View directory record Official record
Conditions
Drug Abuse/Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jun 10, 2026, 10:02 AM EDT
Recruiting No phase listed Observational

Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors

NCT05073848
View directory record Official record
Conditions
Cancer Remission
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

NCT03861234
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
BI 836880
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • New York, New York • Eugene, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

NCT03751007
View directory record Official record
Conditions
Diabetes type1
Interventions
AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose
Biological · Drug
Lead sponsor
Precigen Actobio T1D, LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children

NCT00000811
View directory record Official record
Conditions
Bacterial Infections, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Azithromycin, Atovaquone, Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 18 Months
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

NCT00426998
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Verteporfin, Bevacizumab
Drug
Lead sponsor
Retinal Consultants Medical Group
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Engaging Fathers in Home Visitation

NCT01851577
View directory record Official record
Conditions
Interparental Conflict, Parenting, Parent-child Relations, Fathers
Interventions
Family Foundations coparenting program, Home visiting
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Jun 10, 2026, 10:02 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06769048
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Placebo-matching BI 1584862, BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 10, 2026, 10:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder

NCT03829787
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Eye tracking
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

NCT02559973
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, SUBOXONE Sublingual Film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Jun 10, 2026, 10:02 AM EDT
Recruiting No phase listed Observational

Understanding the Associations Between Romantic Relationship Conflict, Psychophysiological Responding and Alcohol Misuse Among Emerging Adults

NCT06976528
View directory record Official record
Conditions
Heavy Episodic Drinking
Interventions
Not listed
Lead sponsor
New York University
Other
Eligibility
21 Years to 29 Years
Enrollment
160 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jun 10, 2026, 10:02 AM EDT
Terminated Not applicable Interventional

Does a Video-based Education Tool Related to Strengthening Result in Different Functional Outcomes Compared to Traditional Physical Therapy Education for Patients?

NCT04245852
View directory record Official record
Conditions
Patients Receiving Physical Therapy
Interventions
Strength education video, standard PT care
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence

NCT00134914
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1998
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Impact of Different Educational Approaches on Post-operative Opiate Utilization After Elective Lower Extremity Surgery

NCT02997644
View directory record Official record
Conditions
Knee Injuries and Disorders, Hip Injuries and Disorders, Opiate Addiction
Interventions
Video Education, Usual Care Group
Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jun 10, 2026, 10:02 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

NCT03137030
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jun 10, 2026, 10:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry

NCT05384470
View directory record Official record
Conditions
Opiate Abuse, Marijuana Abuse, Diagnostic
Interventions
Marihuana, BID2 Instrument - breathalyzer
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jun 10, 2026, 10:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Race, Ethnicity, Socioeconomic Status and Prolapse-rElated Decisional ConflicT

NCT04977141
View directory record Official record
Conditions
Pelvic Organ Prolapse, Prolapse, Urogenital
Interventions
Decisional Conflict Scale
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Heart to Heart: Testing a Sexual Health Training for Foster and Kinship Caregivers

NCT03331016
View directory record Official record
Conditions
Sexual Behavior, Conflict, Family, Pregnancy Related, Sexually Transmitted Diseases, Family and Household
Interventions
Heart to Heart Training
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Pasadena, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Jun 10, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06006585
View directory record Official record
Conditions
Geographic Atrophy
Interventions
BI 771716
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Walnut Creek, California • Jacksonville, Florida • Melbourne, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jun 10, 2026, 10:02 AM EDT